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Background: In studies and surveys involving stable coronary artery dis-
ease (CAD) patients, the global population often seems well managed; how-
ever, the question remains to know what is the proportion of patients who
benefit from every simple medical intervention improving the prognosis or
showing good quality of care.
Objective: To evaluate medical management of stable CAD outpatients in
France by calculating a progressive quality index.
Methods and Results: The INDYCE survey was conducted in a sample of
343 cardiologists in France in 2008. Each physician had to include consecu-
tively 10 stable CAD patients (absence of acute coronary syndrome or revas-
cularisation in the 6 months preceding enrolment).
3119 patients (male: 80 %, 68 ± 11 years old, diabetes: 24.3 %, hyperten-
sion: 61.6 %) were enrolled.
Medical therapy was in keeping with Guidelines (antiplatelet agents (AA) :
88.4 % ; statins : 85.9 % ; ACE-I/ARBs : 78.8 %, beta-blockers (BB) : 74.6
%). Patients suffered from mild to moderate symptoms (angina : 19.2 %,
NYHA class 0 or I : 43.5 %, NYHA class II : 46.9 %, NYHA class III : 9.3
% ; NYHA class IV : 0.3 %). Mean rest heart rate (HR) was of 64.2 ± 10.8
bpm, mean systolic and diastolic blood pressure (BP) of 131.8 ± 15.4 and 75.8
± 8.4 mmHg respectively.
However, when calculating a progressive quality index: 
(1) 44.69 % of the patients received an AA + a statin + an ACE-I/ARBs + a
BB
(2) 29.79 % had (1) and a systolic BP < 140 mmHg + a diastolic BP < 90
mmHg
(3) 23.02 % had (1) + (2) and a resting heart rate < 70 bpm
(4) 12.6 % had (1) + (2) + (3) and had a regular physical activity
(5) 6.96 % had (1) + (2) + (3) + (4) and had performed an exercise test during
the last 12 months
(6) 4.07 % had (1) + (2) + (3) + (4) + (5) and were asymptomatic (no angina
and NYHA class 0 or I)
Conclusion: Stable CAD patients do not raise attention because they are
often pauci-symptomatic. At a population level, they appear to be well man-
aged. However, building a quality index allows us to show that very few of
these patients benefit from every step of a simple medical management.
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The increased use of interventional cardiology (IC) procedures, while pro-
viding important benefits to patients, also contributes to their radiation expo-
sure. Radiation is a relatively weak carcinogen and demonstrating a radiation-
induced cancer risk remains difficult. Only very crude results of lifetime risk
assessment of cancer after IC procedures have been presented elsewhere, but
the age distribution of population, technical procedures actually applied and
target organs are also important to consider.
Based on a previous detailled description of clinical features and dosimetric
data (absorbed organ doses: lung and bone marrow) of an adult French popu-
lation undergoing IC procedure, and the latest radiation risk models (BEIR
VII), a specific risk assessment for lung cancer and leukaemia mortalities was
realized.
We considered patients having undergone either a coronary angiography or
cumulating coronary angiography and angioplasty, at age 40-75 years, and fol-
lowed until 85 years. Based on different scenarios of radiation exposure and
delivered-doses, the number of deaths from lung cancer or leukaemia due to
radiation per 1,000 general population spontaneous lung cancer or leukaemia
deaths respectively, was estimated. Preliminary results show that the risk of
specific radio-induced cancer in patients undergoing IC procedure exists even
if it remains relatively limited. Moreover, depending on patients’ age and type
of IC procedure, additional procedures appeared to increase the lifetime risk
estimates.
This study provides evidence of the potential radio-induced cancer risk in
IC. The limitations of such calculations are due to the difficulty to take into
account patients’ possible shorter life prognosis than in general population,
partly explained by comorbidities and coronary disease. Because of numerical
evolution of IC procedures, interventions to promote delivered-doses optimi-
zation and “ALARA” requirements may prevent or limit this risk.
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Despite the availability of specific guidelines, the management of dyslipi-
demia in practice is not optimal.
Objective and methodology: PRYSME, a non-interventional multicentre
study carried out with 1226 general practitioners, aimed to describe the imple-
mentation time of a lipid lowering treatment according to cardiovascular risk
level (primary objective) and to identify its determinants. Were eligible
patients treated for a dyslipidemia diagnosed less than 2 years ago. Demo-
graphic and clinical characteristics and circumstances of diagnosis and treat-
ment initiation were collected.
Results: 3268 patients were included (mean age: 57 years old, males:
64%). 26% were obese and 45% overweight.Only 12% had no cardiovascular
risk factors (CRF) at the time of dyslipidemia diagnosis. The most frequent
CRF were arterial hypertension (50%), smoking (43%), family history of pre-
mature coronary heart disease (28%), HDL-c <0.4g/l (20%) whereas 15% of
the patients had a personal history of cardiovascular disease. Dietary programs
were initially implemented for 98% of the patients. More than 90% were
treated with a statin. The implementation time of the treatment (evaluated
according to the biological confirmation of dyslipidemia), according to the ini-
tial number of CRF, was as following: 
The main determinant of an early implementation of a lipid lowering
therapy (≤ 3 months) was secondary prevention (OR=1.8). The number of
CRF had no significant impact.
 0 CRF 1 CRF 2 CRF ≥ 3 CRF Secondary prevention Total
[-3;0] months 34.3% 28.6% 27.1% 29.3% 49.1% 33.1%
]0;3] months 23.1% 26.2% 26.4% 24.0% 21.9% 23.9%
> 3 months 42.6% 45.3% 46.5% 46.8% 29.0% 43.0%
Chi-2 test : P<0.001
